Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Ghezzi

Showing results (51-60 of 133) with videos related to

Pageof 14
Sort By:
Neuroimage|July 26, 2003
Functional cortical changes in patients with multiple sclerosis and nonspecific findings on conventional magnetic resonance imaging scans of the brainMaria A Rocca, Elisabetta Pagani, Angelo Ghezzi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 4, 2008
Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patientsMarco Capobianco, Annalisa Rizzo, Simona Malucchi, et al.
Neuroimage|December 25, 2007
The topographical distribution of tissue injury in benign MS: a 3T multiparametric MRI studyAntonia Ceccarelli, Maria A Rocca, Elisabetta Pagani, et al.
Neurology and Therapy|November 12, 2018
Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl<sup>®</sup>Pietro Annovazzi, Antonio Bertolotto, Vincenzo Brescia Morra, et al.
Experimental Neurology|October 1, 2008
Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosisMauro Zaffaroni, Franca Marino, Raffaella Bombelli, et al.
Neurology and Therapy|August 2, 2017
A Comprehensive Review on Copemyl<sup>®</sup>Pietro Annovazzi, Antonio Bertolotto, Vincenzo Brescia Morra, et al.
Journal of Neuroimmunology|April 19, 2005
Interferon-gamma and interferon-beta affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosisMarco Cosentino, Mauro Zaffaroni, Marco Ferrari, et al.
BMC Neurology|September 27, 2015
Natalizumab in the pediatric MS population: results of the Italian registryAngelo Ghezzi, Lucia Moiola, Carlo Pozzilli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 28, 2016
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapiesDamiano Baroncini, Angelo Ghezzi, Pietro O Annovazzi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 8, 2009
Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosisAntonia Ceccarelli, Maria A Rocca, Mohit Neema, et al.
Pageof 14

Showing results (51-60 of 133) with videos related to

Sort By:
Pageof 14
Neuroimage|July 26, 2003
Functional cortical changes in patients with multiple sclerosis and nonspecific findings on conventional magnetic resonance imaging scans of the brainMaria A Rocca, Elisabetta Pagani, Angelo Ghezzi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 4, 2008
Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patientsMarco Capobianco, Annalisa Rizzo, Simona Malucchi, et al.
Neuroimage|December 25, 2007
The topographical distribution of tissue injury in benign MS: a 3T multiparametric MRI studyAntonia Ceccarelli, Maria A Rocca, Elisabetta Pagani, et al.
Neurology and Therapy|November 12, 2018
Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl<sup>®</sup>Pietro Annovazzi, Antonio Bertolotto, Vincenzo Brescia Morra, et al.
Experimental Neurology|October 1, 2008
Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosisMauro Zaffaroni, Franca Marino, Raffaella Bombelli, et al.
Neurology and Therapy|August 2, 2017
A Comprehensive Review on Copemyl<sup>®</sup>Pietro Annovazzi, Antonio Bertolotto, Vincenzo Brescia Morra, et al.
Journal of Neuroimmunology|April 19, 2005
Interferon-gamma and interferon-beta affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosisMarco Cosentino, Mauro Zaffaroni, Marco Ferrari, et al.
BMC Neurology|September 27, 2015
Natalizumab in the pediatric MS population: results of the Italian registryAngelo Ghezzi, Lucia Moiola, Carlo Pozzilli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 28, 2016
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapiesDamiano Baroncini, Angelo Ghezzi, Pietro O Annovazzi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 8, 2009
Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosisAntonia Ceccarelli, Maria A Rocca, Mohit Neema, et al.
Pageof 14